Opinion|Videos|August 22, 2024
Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments
Medical experts explore how patient perceptions of rheumatoid arthritis can differ from disease activity assessments and provide an example of hidden symptoms revealed through further probing, along with the impact of therapy adjustments on achieving remission.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In your experience, how does a patient’s perception of their disease differ from results of disease activity assessments?
- Can you give an example of a patient who appeared to have controlled disease, but when probed further, you found that there were hidden rheumatoid arthritis symptoms?
- When therapy was adjusted, did the patient achieve remission?
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement